Google’s AI Co-Scientist: A Leap Forward in Biomedical Research
/0 Comments/in Artificial Intelligence/by MaxOncoACP3: A Potential Game-Changer in Prostate Cancer Theranostics —Why?
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 8/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This time, I welcome you with the Milky Way! This week, we have some exciting updates on cutting-edge treatments in clinical and preclinical trials. I hope you find them as fascinating as I do! I bet you can guess […]
ENV105 to Reverse Resistance to ADT and ARSI
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxUpdate: 67Cu-SAR-bisPSMA for mCRPC Has Been Fast-Tracked by FDA
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA New Compound Looks Promising for Bone Metastasis
/0 Comments/in Not PCa related, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
abiraterone acetate ADC ADT AI ai in healthcare alphafold androgen deprivation therapy antibody-drug conjugate apalutamide artificial intelligence ATM bispecific antibody bone metastasis BRCA cancer immunotherapy cancer treatment clinical trial clinical trials crispr darolutamide diet drug discovery drug repurposing drug resistance enzalutamide gut microbiome immunotherapy mcrpc metastatic cancer metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology Nectin-4 oncology oncolytic virus PARP inhibitor personalized medicine prostate cancer PSMA radioligand therapy real-world data T-cell therapy theranostics
Latest Posts
- SECuRE Trial Update: Promising Results in Metastatic Castration-Resistant Prostate Cancer March 7, 2025
- Phase 3 Trial: 225-Ac-PSMA-617 + ARPI vs SOC March 6, 2025
- FG-3246 Advances to Phase 2 Trial in Prostate Cancer After Promising Early Results March 6, 2025
- Macrophage-Drug Conjugates: A New Frontier in Cancer Treatment March 5, 2025